A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
type: MedicalStudy
description: A Phase 2, Safety and Efficacy Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
status: TERMINATED
study design: INTERVENTIONAL
phase: PHASE2
start date: 2025-06-03
end date: 2026-01-23
license: https://creativecommons.org/publicdomain/zero/1.0/
source: https://clinicaltrials.gov/study/NCT06682806
source organization: US National Library of Medicine
publisher: AI Analytics
sponsor: Prelude Therapeutics
study subject: Advanced Solid Tumor
study subject: Esophageal Cancer
study subject: Metastatic Solid Tumor
study subject: Non-small Cell Lung Cancers
study subject: SMARCA4 Gene Mutation
keywords: PHASE2
keywords: INTERVENTIONAL
keywords: TERMINATED
keywords: Advanced Solid Tumor
keywords: Esophageal Cancer
keywords: Metastatic Solid Tumor
keywords: Non-small Cell Lung Cancers
keywords: SMARCA4 Gene Mutation

AI Analytics
type: Organization